RNA-binding proteins (RBPs) play an important role in RNA metabolism, regulating the stability, localization, and functional dynamics of RNAs. Alternation in the RBP-RNA network has profound implications in cellular physiology, and is related to the development and spread of cancer in certain cases. To regulate the expression of specific genes and their biological activities, various strategies have been applied to target RBPs for cancer treatments, including small-molecule inhibitors, small-interfering RNA, peptides, and aptamers. Recently, the deployment of the CRISPR-Cas9 technology has provided a new platform for RBP screening and regulation. This review summarizes the delivery systems of the CRISPR-Cas9 system and their role in RBP-based cancer therapeutics, including identification of novel RBPs and regulation of cancer-associated RBPs. The efficient delivery of the CRISPR-Cas9 system is important to the profound understanding and clinical transition of RBPs as cancer therapeutic targets.

RNA 结合蛋白 (RBP) 在 RNA 代谢中发挥重要作用，调节 RNA 的稳定性、定位和功能动力学。RBP-RNA 网络的交替对细胞生理学具有深远的影响，并且在某些情况下与癌症的发展和扩散有关。为了调节特定基因的表达及其生物活性，已经应用各种策略来靶向 RBP 进行癌症治疗，包括小分子抑制剂、小干扰 RNA、肽和适体。最近，CRISPR-Cas9 技术的部署为 RBP 筛选和监管提供了一个新的平台。本综述总结了 CRISPR-Cas9 系统的传递系统及其在基于 RBP 的癌症治疗中的作用，包括新型 RBP 的鉴定和癌症相关 RBP 的调节。